Home LiteratureArticle Details
PMID: 19016756 Published · ppublish English

Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer.

Cancer science ·Vol. 99 ·No. 10 ·2008-12-17

Sugano Kokichi, Nakamura Seigo, Ando Jiro, Takayama Shin, Kamata Hiroyuki, Sekiguchi Isao, Ubukata Megumi, Kodama Tetsuro, Arai Masami, Kasumi Fujio, Hirai Yasuo, Ikeda Tadashi, Jinno Hiromitsu, Kitajima Masaki, Aoki Daisuke, Hirasawa Akira, Takeda Yuko, Yazaki Kumiko, Fukutomi Takashi, Kinoshita Takayuki, Tsunematsu Ryuichiro, Yoshida Teruhiko, Izumi Masako, Umezawa Shino, Yagata Hiroshi, Komatsu Hiroko, Arimori Naoko, Matoba Noriko, Gondo Nobuhisa, Yokoyama Shiro, Miki Yoshio

Abstract

The prevalence of BRCA1/2 germline mutations in Japanese patients suspected to have hereditary breast/ovarian cancer was examined by a multi-institutional study, aiming at the clinical application of total sequencing analysis and validation of assay sensitivity in Japanese people using a cross-sectional approach based on genetic factors estimated from personal and family histories. One hundred and thirty-five subjects were referred to the genetic counseling clinics and enrolled in the study. Full sequencing analysis of the BRCA1/2 gene showed 28 types of deleterious mutations in 36 subjects (26.7%), including 13 types of BRCA1 mutations in 17 subjects (12.6%) and 15 types of BRCA2 mutations in 19 subjects (14.1%). Subjects were classified into five groups and 22 subgroups according to their personal and family history of breast and/or ovarian cancer, and the prevalence of deleterious mutations was compared with previously reported data in non-Ashkenazi individuals. Statistical analysis using the Mantel-Haenszel test for groups I through IV revealed that the prevalence of Japanese subjects was significantly higher than that of non-Ashkenazi individuals (P = 0.005, odds ratio 1.87, 95% confidence interval 1.22-2.88). Family history of the probands suffering from breast cancer indicated risk factors for the presence of deleterious mutations of BRCA1/2 as follows: (1) families with breast cancer before age 40 within second degree relatives (P = 0.0265, odds ratio 2.833, 95% confidence interval 1.165-7.136) and (2) families with bilateral breast cancer and/or ovarian cancer within second degree relatives (P = 0.0151, odds ratio 2.88, 95% confidence interval 1.25-6.64).

Article Info
Journal
Cancer science
Abbr.
Cancer Sci
Published
2008-12-17
Indexed
2008-11-21
Updated
2009-11-19
Language
English
Country/Region
England
NLM ID
101168776
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com